by Angela Guess

A recent press release reports, “The Human Vaccines Project is teaming with the University of California San Diego to apply advances in machine learning to solve critical problems impeding the development of vaccines and therapeutics for a wide range of diseases. The Human Vaccines Project (Project) is a new global public-private partnership of academic research centers, industry, non-profits and government agencies designed to accelerate the development of next-generation vaccines and immunotherapies.”

Wayne C. Koff, Ph.D., President and CEO of the Human Vaccines Project, commented, “The Human Vaccines Project has embarked on a decade-long, $1 billion mission to decode the human immune system… Information technology, machine learning and computational biology all hold important keys to developing vaccines against immune-mediated diseases, including global killers such as HIV and tuberculosis (TB), emerging diseases such as Zika and pandemic flu, cancers, allergies and autoimmune disorders.”

The release goes on, “Under a scientific plan endorsed by 35 of the world’s leading vaccine scientists, the Project aims to apply recent advances in machine learning and data science to speed vaccine development. ‘Applying machine learning should accelerate the development of new vaccines and therapies for a wide range of pressing diseases,’ said UC San Diego computer scientist and physicist Larry Smarr, director of Calit2. ‘In addition to machine learning, experts in Big Data analytics, pattern recognition, genomics and bioinformatics can also help us understand the fundamental principles of effective human immunity, and enable the design of highly-targeted vaccines’.”

Read more at PRWeb.

Photo credit: Flickr/ Carlos Reusser Monsalvez